It has been previously reported that CCNE1-amplification, which occurs in 15–20% of high-grade serous ovarian cancer (HGSOC) patient tumors, generally does not co-occur with loss of function mutations of HR genes (4,5). Here, CCNE1 is linked to ovarian serous adenocarcinoma.